By Melanie Senior
In 2001 GlaxoSmithKline PLC made one of the boldest, and certainly most visible, structural reforms to boost its pitiful...
GSK's Risk-Sharing Deals to Compete with In-House R&D
Convinced of the merits of its Center of Excellence set-up across R&D, GSK has built another unit focused exclusively on external drug discovery, with a broader, risk-sharing deal-style. The aim is to expand R&D without increasing the company's size.